Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

The use of a new generation low molecular weight heparin (Bemiparin)and the well known LMWH (Enoxaparin) after Caesarean sections and vaginal deliveries in a risky group patients for venous thrombosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hawler Medical University
• Treatments: Bemiparin; Calcium heparin; Dalteparin; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight

Criteria

Inclusion Criteria:

• Presence of risk factors for venous thromboembolism

• Any parity

• Mode of delivery:vaginal, Emergency and Elective Caesarean section

• No any contraindications for Heparin

Exclusion Criteria:

• Active antenatal or postpartum vaginal bleeding.

• Placenta previa

• Thrombocytopenia

• Sever renal or liver diseases

• Uncontrolled sever hypertension

• Any patient who is already on Heparin during pregnancy